Clinical Trials

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

55 enrolled

Neoplasm Metastasis

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

28 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

40 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT02787642 2026-02-25

RADIOSARP

41 enrolled 15 charts

Sarcoma

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

10 enrolled

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06331559 2026-02-09

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled

Advanced Solid Tumors

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT06560632 2026-01-16

POLAR

Phase 1 Terminated

26 enrolled 14 charts

Advanced Solid Tumor

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

197 enrolled

Solid Tumors

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

50 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02546661 2025-12-29

BISCAY

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03955640 2025-12-22

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase 1 Terminated

3 enrolled

Breast Neoplasms

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

49 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Ewing

NCT04550104 2025-12-19

CONCORDE

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05240898 2025-12-18

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

116 enrolled

Advanced Solid Tumors

NCT03109080 2025-11-24

RadioPARP

24 enrolled

Radiation Injuries, Triple Negative Breast Neoplasms

NCT05900895 2025-11-20

PHOEBE

6 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

50 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04197713 2025-10-20

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

13 enrolled 13 charts

Neoplasm Metastasis

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

90 enrolled

Breast Neoplasms

NCT03842228 2025-10-14

COD

39 enrolled 15 charts

Neoplasm Metastasis

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Other solid neoplasmThoracic

52 enrolled

Advanced Solid Tumor

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

429 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

20 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07090369 2025-07-29

LumOnate

20 enrolled

Genitourinary

Prostatic Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT05870423 2025-06-05

PRRT-PARPi

24 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT03874884 2025-05-14

LuPARP

70 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT04236414 2025-04-04

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

16 enrolled